Fierce HCIndustry
'Hospitals adverse to transparency'—clashing industry groups spar on mulligan 340B rebate pilot
Summary
The administration's second stab at a rebate program for statutory drug discounts drew familiar arguments and new alarm bells over a potential expansion from last year's aborted iteration of the pharma-friendly pilot program.
The administration's second stab at a rebate program for statutory drug discounts drew familiar arguments and new alarm bells over a potential expansion from last year's aborted iteration of the pharma-friendly pilot program.